Literature DB >> 19918056

Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling.

Pamina Pflegerl1, Paul Vesely, Brigitte Hantusch, Michaela Schlederer, Rainer Zenz, Elke Janig, Günter Steiner, Arabella Meixner, Peter Petzelbauer, Peter Wolf, Afschin Soleiman, Gerda Egger, Richard Moriggl, Tadamitsu Kishimoto, Erwin F Wagner, Lukas Kenner.   

Abstract

Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting various tissues. Involvement of B and T cells as well as increased cytokine levels have been associated with disease manifestation. Recently, we demonstrated that mice with epidermal loss of JunB (JunB(Deltaep)) develop a myeloproliferative syndrome (MPS) due to high levels of G-CSF which are secreted by JunB-deficient keratinocytes. In addition, we show that JunB(Deltaep) mice develop a SLE phenotype linked to increased epidermal interleukin 6 (IL-6) secretion. Intercrosses with IL-6-deficient mice could rescue the SLE phenotype. Furthermore, we show that JunB binds to the IL-6 promoter and transcriptionally suppresses IL-6. Facial skin biopsies of human SLE patients similarly revealed low JunB protein expression and high IL-6, activated Stat3, Socs-1, and Socs-3 levels within lupus lesions. Thus, keratinocyte-induced IL-6 secretion can cause SLE and systemic autoimmunity. Our results support trials to use alpha-IL-6 receptor antibody therapy for treatment of SLE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19918056      PMCID: PMC2787143          DOI: 10.1073/pnas.0910371106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo.

Authors:  F Eitner; R Westerhuis; M Burg; B Weinhold; H J Gröne; T Ostendorf; U Rüther; K M Koch; A J Rees; J Floege
Journal:  Kidney Int       Date:  1997-01       Impact factor: 10.612

2.  Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice.

Authors:  A Katsume; T Miyai; H Suzuki; Y Moriguchi; H Kawata; T Tatsumi; S Suematsu; T Kishimoto; Y Ohsugi
Journal:  Clin Immunol Immunopathol       Date:  1997-02

3.  Cellular localization of inflammatory cytokines in human glomerulonephritis.

Authors:  T Takemura; K Yoshioka; K Murakami; N Akano; M Okada; N Aya; S Maki
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

4.  Presence of tumor necrosis factor alpha and interleukin-6 in renal mesangial cells of lupus nephritis patients.

Authors:  D Malide; P Russo; M Bendayan
Journal:  Hum Pathol       Date:  1995-05       Impact factor: 3.466

5.  Interleukin-6 receptor blockage ameliorates murine lupus nephritis.

Authors:  B A Kiberd
Journal:  J Am Soc Nephrol       Date:  1993-07       Impact factor: 10.121

6.  Interleukin-6 exacerbates glomerulonephritis in (NZB x NZW)F1 mice.

Authors:  B Ryffel; B D Car; H Gunn; D Roman; P Hiestand; M J Mihatsch
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

7.  Impaired immune and acute-phase responses in interleukin-6-deficient mice.

Authors:  M Kopf; H Baumann; G Freer; M Freudenberg; M Lamers; T Kishimoto; R Zinkernagel; H Bluethmann; G Köhler
Journal:  Nature       Date:  1994-03-24       Impact factor: 49.962

8.  Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus.

Authors:  W Hassfeld; G Steiner; A Studnicka-Benke; K Skriner; W Graninger; I Fischer; J S Smolen
Journal:  Arthritis Rheum       Date:  1995-06

9.  The weight of interleukin-6 in B cell-related autoimmune disorders.

Authors:  Pierre Youinou; Christophe Jamin
Journal:  J Autoimmun       Date:  2009 May-Jun       Impact factor: 7.094

10.  The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells.

Authors:  Oliver Dienz; Sheri M Eaton; Jeffrey P Bond; Wendy Neveu; David Moquin; Rajkumar Noubade; Eva M Briso; Colette Charland; Warren J Leonard; Gennaro Ciliberto; Cory Teuscher; Laura Haynes; Mercedes Rincon
Journal:  J Exp Med       Date:  2009-01-12       Impact factor: 14.307

View more
  33 in total

1.  Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-β1 transgenic mice.

Authors:  Tej Pratap Singh; Barbara Huettner; Harald Koefeler; Gerlinde Mayer; Isabella Bambach; Katrin Wallbrecht; Michael P Schön; Peter Wolf
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

2.  In vivo siRNA targeting of CD28 reduces UV-induced DNA damage and inflammation.

Authors:  Tej Pratap Singh; Gerlinde Mayer; Peter Wolf
Journal:  J Invest Dermatol       Date:  2013-09-16       Impact factor: 8.551

3.  Genetic disruption of Fra-1 decreases susceptibility to endotoxin-induced acute lung injury and mortality in mice.

Authors:  Michelle Vaz; Narsa M Reddy; Subbiah Rajasekaran; Sekhar P Reddy
Journal:  Am J Respir Cell Mol Biol       Date:  2012-01       Impact factor: 6.914

4.  Lupus Skin Is Primed for IL-6 Inflammatory Responses through a Keratinocyte-Mediated Autocrine Type I Interferon Loop.

Authors:  Jasmine N Stannard; Tamra J Reed; Emily Myers; Lori Lowe; Mrinal K Sarkar; Xianying Xing; Johann E Gudjonsson; J Michelle Kahlenberg
Journal:  J Invest Dermatol       Date:  2016-09-16       Impact factor: 8.551

5.  Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling.

Authors:  Christian M Hedrich; Thomas Rauen; Sokratis A Apostolidis; Alexandros P Grammatikos; Noe Rodriguez Rodriguez; Christina Ioannidis; Vasileios C Kyttaris; Jose C Crispin; George C Tsokos
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-03       Impact factor: 11.205

6.  Effects of the loss of conjunctival Muc16 on corneal epithelium and stroma in mice.

Authors:  Kumi Shirai; Yuka Okada; Dong-Joo Cheon; Masayasu Miyajima; Richard R Behringer; Osamu Yamanaka; Shizuya Saika
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

Review 7.  Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances.

Authors:  Desmond Yat Hin Yap; Kar Neng Lai
Journal:  J Biomed Biotechnol       Date:  2010-05-06

8.  Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis.

Authors:  David Berry; Clarissa Schwab; Gabriel Milinovich; Jochen Reichert; Karim Ben Mahfoudh; Thomas Decker; Marion Engel; Brigitte Hai; Eva Hainzl; Susanne Heider; Lukas Kenner; Mathias Müller; Isabella Rauch; Birgit Strobl; Michael Wagner; Christa Schleper; Tim Urich; Alexander Loy
Journal:  ISME J       Date:  2012-05-10       Impact factor: 10.302

9.  PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.

Authors:  Daniela Laimer; Helmut Dolznig; Karoline Kollmann; Paul W Vesely; Michaela Schlederer; Olaf Merkel; Ana-Iris Schiefer; Melanie R Hassler; Susi Heider; Lena Amenitsch; Christiane Thallinger; Philipp B Staber; Ingrid Simonitsch-Klupp; Matthias Artaker; Sabine Lagger; Suzanne D Turner; Stefano Pileri; Pier Paolo Piccaluga; Peter Valent; Katia Messana; Indira Landra; Thomas Weichhart; Sylvia Knapp; Medhat Shehata; Maria Todaro; Veronika Sexl; Gerald Höfler; Roberto Piva; Enzo Medico; Bruce A Ruggeri; Mangeng Cheng; Robert Eferl; Gerda Egger; Josef M Penninger; Ulrich Jaeger; Richard Moriggl; Giorgio Inghirami; Lukas Kenner
Journal:  Nat Med       Date:  2012-10-14       Impact factor: 53.440

10.  Dysregulation of the suppressor of cytokine signalling 3-signal transducer and activator of transcription-3 pathway in the aetiopathogenesis of Sjögren's syndrome.

Authors:  S R Vartoukian; W M Tilakaratne; N Seoudi; M Bombardieri; L Bergmeier; A R Tappuni; F Fortune
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.